Medicine & Life Sciences
Inflammatory Breast Neoplasms
100%
Breast Neoplasms
99%
Triple Negative Breast Neoplasms
93%
Neoplasms
44%
Drug Therapy
33%
Neoadjuvant Therapy
32%
TIC10 compound
32%
human ERBB2 protein
22%
Neoplasm Metastasis
21%
Therapeutics
20%
Circulating Neoplastic Cells
19%
Survival
17%
Mitogen-Activated Protein Kinase Kinases
14%
Hormones
12%
Estrogen Receptors
12%
Androgen Receptors
12%
Tumor Microenvironment
11%
Mutation
11%
N-(4-(3-chloro-4-(2-pyridinylmethoxy)anilino)-3-cyano-7-ethoxy-6-quinolyl)-4-(dimethylamino)-2-butenamide
11%
Epidermal Growth Factor
11%
Tumor-Infiltrating Lymphocytes
11%
trametinib
10%
Lobular Carcinoma
10%
Trastuzumab
9%
Clinical Trials
9%
Biomarkers
9%
Adenoviridae
9%
Breast
9%
TNF-Related Apoptosis-Inducing Ligand
9%
HM781-36B
9%
Apoptosis
8%
entinostat
8%
Modified Radical Mastectomy
8%
Fluorescence In Situ Hybridization
7%
Oxidative Phosphorylation
7%
Ductal Carcinoma
7%
Phosphatidylinositol 3-Kinases
7%
sapanisertib
7%
N-(2,3-dihydroxypropyl)-1-((2-fluoro-4-iodophenyl)amino)isonicotinamide
7%
Telomerase
7%
Mastectomy
6%
Cell Line
6%
mirvetuximab soravtansine
6%
Progression-Free Survival
6%
human TNFSF10 protein
6%
Colorectal Neoplasms
6%
Epithelial-Mesenchymal Transition
6%
birinapant
6%
Everolimus
5%
talimogene laherparepvec
5%